Abstract
The Option and Evaluation Agreements in Pharma and Biotech report provides
comprehensive understanding and unprecedented access to the option and
evaluation partnering agreements entered into by the worlds leading biopharma
companies.
This report provides details of the latest option and evaluation agreements
announced in the pharmaceutical and biotechnology sectors. Detailed and
comprehensive, the report provides details of option and evaluation agreements
from 2003 to end 2008.
The report provides a detailed understand and analysis of how and why
companies enter option and evaluation deals. The majority of deals are option
agreements whereby one party to the agreement obtains an option right from the
other party. Understanding the flexibility of a prospective partner' s
negotiated deals terms provides critical insight into the negotiation process
in terms of what you can expect to achieve during the negotiation of terms.
Whilst many smaller companies will be seeking details of the payments clauses,
the devil is in the detail in terms of how payments are triggered - contract
documents provide this insight where press releases and databases do not.
This report contains over 400 links to online copies of actual option and
evaluation contract documents as submitted to the Securities Exchange
Commission by pharma/biotech companies and their partners.
Contract documents provide the answers to numerous questions about a
prospective partner' s flexibility on a wide range of important issues, many of
which will have a significant impact on each party' s ability to derive value
from the deal.
The initial chapters of this report provide an orientation of option and
evaluation dealmaking and business activities. Chapter 1 provides a brief
introduction to the report, whilst chapter 2 provides an analysis of the
trends in option and evaluation as well as a discussion on the merits of each
type of deal. Chapter 3 provides an overview of the structure of option and
evaluation deals. The chapter includes numerous case studies to enable
understanding of both option and evaluation deals where partnering or
acquisition is the primary focus of the agreement.
Chapter 4 provides a review of the leading option and evaluation deals since
2000. Deals are listed by headline value and most active bigpharma. Where the
deal has an agreement contract published at the SEC a link provides online
access to the contract.
Chapter 5 provides a comprehensive listing of the top 50 bigpharma companies
with a brief summary including option and evaluation frequency followed by a
comprehensive listing of option and evaluation contract documents available in
the public domain. Each deal title links via Weblink to an online version of
the actual contract document, providing easy access to each contract document
on demand.
Chapter 6 provides a comprehensive listing of all option and evaluation
agreement contracts available in the public domain, respectively. The chapter
is organized by A-Z company name, option/evaluation type, therapy area and
stage of development at signing. Each deal title links via Weblink to an
online version of the actual contract document, providing easy access to each
contract document on demand.
| 
View Cart
